AI Beneficiaries: Biopharma

In this week's market update, we explore why biopharma may be one of the most compelling long-term beneficiaries of AI. While much of the market's attention has focused on companies building AI infrastructure and models, we believe the larger opportunity may lie in industries where AI can improve productivity, reduce costs, and accelerate innovation.Topics covered include:• Why biopharma's high R&D spending makes it a natural candidate for AI adoption• The industry's growing productivity challenges and how AI may help address them• Recent scientific breakthroughs from companies like Eli Lilly and Company and Verve Therapeutics• The rise of AI-driven drug discovery platforms, including Isomorphic Labs• Increasing AI investment from major pharmaceutical companies• Why biopharma may be positioned for improved fundamentals after years of underperformanceAs always, if you have questions or would like to discuss potential investment opportunities, please feel free to reach out.Subscribe for weekly macro updates and portfolio strategies.Visit our website: https://fortllc.com/Reach out: [email protected]#ArtificialIntelligence #AI #Biotech #Biopharma #Investing #StockMarket #HealthcareInnovation #DrugDiscovery #MarketUpdate #WealthManagement #FortSheridanAdvisors_______________________________________________________________Investing involves risk, including the possible loss of principal and fluctuation of value. Past performance is no guarantee of future results. This presentation is not intended to be relied upon as forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of the date noted and may change as subsequent conditions vary. The information and opinions contained in this presentation are derived from proprietary and nonproprietary sources deemed by Fort Sheridan Advisors, LLC to be reliable. The presentation may contain “forward-looking” information that is not purely historical in nature. Such information may include, among other things, projection and forecasts. There is no guarantee that any forecast made will materialize. Reliance upon information in this presentation is at the sole discretion of the investor. Please consult with Fort Sheridan Advisors, LLC financial advisor to ensure that any contemplated transaction in any securities or investment strategy mentioned in this presentation align with your overall investment goals, objectives and tolerance for risk. Additional information about Fort Sheridan Advisors, LLC is available in its current disclosure documents, Form ADV, Form ADV Part 2A Brochure, and Client Relationship Summary report which are accessible online via the SEC’s Investment Adviser Public Disclosure (IAPD) database at www.adviserinfo.sec.gov, using SEC # 801-70517. Fort Sheridan Advisors, LLC is neither an attorney nor an accountant, and no portion of this content should be interpreted as legal, accounting or tax.